Fortress Biotech Files 8-K
Ticker: FBIOP · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1429260
| Field | Detail |
|---|---|
| Company | Fortress Biotech, INC. (FBIOP) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: FBIO
TL;DR
FBIO filed an 8-K, no major news yet.
AI Summary
Fortress Biotech, Inc. filed an 8-K on December 13, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or new developments, but it confirms the company's reporting status.
Why It Matters
This filing indicates that Fortress Biotech, Inc. has made a regulatory submission, which is a standard procedural step for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for an 'Other Event' and does not disclose any new material information that would immediately impact risk.
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- December 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-35366 (filing_id) — Commission File Number
- 20-5157386 (tax_id) — IRS Employer Identification No.
- 1111 Kane Concourse, Suite 301 (address) — Principal Executive Offices
- Bay Harbor Islands, FL 33154 (address) — Principal Executive Offices Location
FAQ
What specific event is Fortress Biotech, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not specify the exact nature of the event.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 13, 2024.
What is the principal executive office address for Fortress Biotech, Inc.?
The principal executive offices are located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
What is the Commission File Number for Fortress Biotech, Inc.?
The Commission File Number is 001-35366.
In which state is Fortress Biotech, Inc. incorporated?
Fortress Biotech, Inc. is incorporated in Delaware.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-16 16:50:22
Filing Documents
- fbio-20241213x8k.htm (8-K) — 37KB
- 0001558370-24-016294.txt ( ) — 217KB
- fbio-20241213.xsd (EX-101.SCH) — 5KB
- fbio-20241213_def.xml (EX-101.DEF) — 15KB
- fbio-20241213_lab.xml (EX-101.LAB) — 13KB
- fbio-20241213_pre.xml (EX-101.PRE) — 15KB
- fbio-20241213x8k_htm.xml (XML) — 7KB
01. Other Events
Item 8.01. Other Events . On December 13, 2024, Checkpoint Therapeutics (" Checkpoint "), a majority-controlled subsidiary of Fortress Biotech, Inc. (the " Company " or " Fortress "), announced that the U.S. Food and Drug Administration (the " FDA ") approved UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (" cSCC ") who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. The FDA approval for UNLOXCYT was granted based on clinically meaningful objective response rates and duration of response data, as assessed by an independent central review committee, from Study CK-301-101 (NCT03212404), a multicenter, multicohort, open-label study of UNLOXCYT in adults with advanced solid tumor cancers, including cSCC. 99
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: December 16, 2024 By: /s/ David Jin David Jin Chief Financial Officer